-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, PharmaEssentia announced that the US FDA has approved the long-acting interferon Besremi (ropeginterferonα-2b-njft) to be marketed for the treatment of adult patients with polycythemia vera (PV)
This approval is based on positive efficacy and safety data obtained in a phase 3 clinical trial
Polycythemia vera is a rare, chronic and fatal blood cancer
Besremi is an innovative monoformylated, long-acting interferon
Reference materials:
[1] US FDA Approves Besremi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.
(The original text has been deleted)